Zug, Switzerland-based dental company vVardis is seeking to raise up to $228.6 million in a U.S. initial public offering at a valuation of up to $4.37 billion, Reuters reported Nov. 6.
The company plans to offer about 9.5 million shares priced between $21 and $24 each.
vVardis makes Curodont, a line of noninvasive treatments designed to repair early-stage tooth decay without drilling or injections. Sales of its flagship U.S. product, Curodont Repair Fluoride Plus, rose 112% in the nine months ended Sept. 30, and the product had been sold to more than 20,000 U.S. dental practices as of June 30, according to a company filing.
The company received a strategic minority investment from funds managed by Apollo Global Management in April.
